{
    "clinical_study": {
        "@rank": "129381", 
        "arm_group": {
            "arm_group_label": "Treatment (exemestane, surgery)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well exemestane before surgery works in treating\n      postmenopausal patients with newly diagnosed estrogen receptor positive stage II-III breast\n      cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using\n      exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells."
        }, 
        "brief_title": "Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Stage II Breast Cancer", 
            "Stage III Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study will develop preliminary data regarding the efficacy and safety of exemestane in\n      the preoperative treatment of postmenopausal women with ER+ or PR+ tumors. This trial is\n      also designed to develop a predictive model to correlate expression of the known isoforms of\n      ER and progesterone receptor (PR) and the aromatase enzyme with response to estrogenic\n      deprivation using exemestane."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed breast cancer\n\n          -  ER positive (+)\n\n          -  Primary tumor 2-4 regional lymph nodes 0-2 (T2-4N0-2); patients may have metastatic\n             disease, provided local-regional surgery is clinically indicated\n\n          -  Clinical stage II/III\n\n          -  Postmenopausal- defined as having had a previous bilateral oophorectomy or, for women\n             with no prior hysterectomy, the absence of spontaneous menstrual cycles for more than\n             1 year\n\n          -  Newly diagnosed\n\n          -  Patients with prior non-breast malignancies are eligible if they have been disease\n             free for >= 5 years before study entry; patients with squamous or basal cell\n             carcinoma of the skin that has been effectively treated, carcinoma in situ of the\n             cervix that has been treated by surgery only, or lobular carcinoma in situ (LCIS) of\n             the ipsilateral or contralateral breast that has been treated by surgery only are\n             eligible, even if the cancer was diagnosed within 5 years before randomization\n\n          -  Serum creatinine =< 1.5 x institutional upper limit of normal (ULN)\n\n          -  Hemoglobin within normal limits for institution\n\n          -  Absolute granulocyte count >= 1500\n\n          -  Platelet count >= 100,000\n\n          -  Serum glutamic oxaloacetic transaminase (SGOT), aspartate aminotransferase (AST) or\n             serum glutamate pyruvate transaminase (SGPT), alanine aminotransferase (ALT) =< 2.5 x\n             ULN\n\n          -  Total bilirubin < 2 x ULN for institution\n\n          -  Alkaline phosphatase < 2 x the ULN\n\n        Exclusion Criteria:\n\n          -  Completely resected\n\n          -  Prior hormone or chemotherapy\n\n          -  Unable to take oral medication\n\n          -  Patients who have nonmalignant systemic disease (cardiovascular, renal, hepatic,\n             etc.) that would preclude their being subjected to protocol therapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01831076", 
            "org_study_id": "01-0627.cc"
        }, 
        "intervention": {
            "arm_group_label": "Treatment (exemestane, surgery)", 
            "description": "Given PO", 
            "intervention_name": "Exemestane", 
            "intervention_type": "Drug", 
            "other_name": [
                "107868-30-4,", 
                "6-Methyleneandrosta-1,", 
                "4-diene-3,17-dione,", 
                "713563,", 
                "Aromasin,", 
                "FCE 24304,", 
                "FCE-24304,", 
                "PNU 155971"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Exemestane"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Breast cancer", 
            "estrogen receptor-positive breast cancer", 
            "progesterone receptor-positive breast cancer", 
            "Postmenopausal", 
            "Exemestane", 
            "Tamoxifen"
        ], 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Aurora", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80045"
                }, 
                "name": "University of Colorado Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors. A Phase II Study to Identify Molecular Predictors for Hormone Responsiveness and/or Resistance.", 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Anthony Elias, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Descriptive analyses will be performed to characterize the variability in the estrogen deprivation levels.", 
            "measure": "Estrogenic deprivation", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01831076"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluated using chi-square analysis.", 
            "measure": "Response rates (RR) as measured by clinical exam, standard imaging, and surgical pathology findings", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 months"
        }, 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}